Wall Street Zen Upgrades Agios Pharmaceuticals to 'Hold'

The biopharmaceutical company's stock rating improved from 'sell' to 'hold' in a new research note.

Mar. 22, 2026 at 5:09am

Got story updates? Submit your updates here. ›

Wall Street Zen, an equity research firm, has upgraded its rating on Agios Pharmaceuticals (NASDAQ:AGIO) from 'sell' to 'hold' in a new research report. The upgrade comes as Agios, a biopharmaceutical company focused on cancer and rare genetic diseases, has seen its stock price fluctuate over the past year.

Why it matters

Agios Pharmaceuticals is a closely watched biotech company developing novel therapies targeting cellular metabolism. The upgrade from Wall Street Zen, while still a 'hold' rating, could signal a shift in sentiment around the company's prospects and pipeline. Investors will be watching to see if other analysts follow suit in the coming weeks.

The details

In its research note, Wall Street Zen cited a number of factors for the rating upgrade, including Agios' recent progress in advancing its lead IDH inhibitor programs and an improved financial position. The firm also noted Agios' stock has traded in a range between $22 and $46 over the past 52 weeks, indicating potential upside from current levels around $28 per share.

  • Agios Pharmaceuticals' stock opened at $27.86 on Friday, March 22, 2026.

The players

Agios Pharmaceuticals

A biopharmaceutical company focused on developing novel therapies for cancer and rare genetic diseases by targeting cellular metabolism.

Wall Street Zen

An equity research firm that covers the biotechnology sector, including Agios Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The upgrade of Agios Pharmaceuticals by Wall Street Zen, while still a 'hold' rating, suggests the biotech company may be turning a corner and could see increased investor interest if it continues to make progress on its drug development pipeline.